发布时间:2019-07-29 22:25 原文链接: SitedirectedMutagenesisusingPCR

Site-directed Mutagenesis using PCR

Michael P. Weiner, Tim Gackstetter, Gina L. Costa, John C. Bauer, and Keith A. Kretz



From: Molecular Biology: Current Innovations and Future Trends. Eds. A.M. Griffin and H.G.Griffin. ISBN 1-898486-01-8 1995 Horizon Scientific Press, PO Box 1, Wymondham, Norfolk, U.K. 


In vitro site-directed mutagenesis is an invaluable technique for studying protein structure-function relationships, gene expression and vector modification. Several methods have appeared in the literature, but many of these methods require single-stranded DNA as the template. The reason for this, historically, has been the need for separating the complementary strands to prevent reannealing. Use of PCR in site-directed mutagenesis accomplishes strand separation by using a denaturing step to separate the complementing strands and allowing efficient polymerization of the PCR primers. PCR site-directed methods thus allow site-specific mutations to be incorporated in virtually any double-stranded plasmid; eliminating the need for M13-based vectors or single-stranded rescue.

Several points should be mentioned concerning site-directed mutagenesis using PCR. First, it is often desirable to reduce the number of cycles during PCR when performing PCR-based site-directed mutagenesis to prevent clonal expansion of any (undesired) second-site mutations. Limited cycling which would result in reduced product yield, is offset by increasing the starting template concentration. Second, a selection must be used to reduce the number of parental molecules coming through the reaction. Third, in order to use a single PCR primer set, it is desirable to optimize the long PCR method. And fourth, because of the extendase activity of some thermostable polymerases it is often necessary to incorporate an end-polishing step into the procedure prior to end-to-end ligation of the PCR-generated product containing the incorporated mutations in one or both PCR primers.

A protocol is provided as a facile method for site-directed mutagenesis and accomplishes the above desired features by the incorporation of the following steps: (i) increasing template concentration approximately 1000-fold over conventional PCR conditions; (ii) reducing the number of cycles from 25-30 to 5-10; (iii) adding the restriction endonuclease DpnI (recognition target sequence: 5-Gm6ATC-3, where the A residue is methylated) to select against parental DNA (note: DNA isolated from almost all common strains of E. coli is Dam-methylated at the sequence 5-GATC-3); (iv) using Taq Extender in the PCR mix for increased reliability for PCR to 10 kb; (v) using Pfu DNA polymerase to polish the ends of the PCR product, and (vi) efficient intramolecular ligation in the presence of T4 DNA ligase.

Protocol. PCR-based Site Directed Mutagenesis

  • Plasmid template DNA (approximately 0.5 pmole) is added to a PCR cocktail containing, in 25 ul of 1x mutagenesis buffer: (20 mM Tris HCl, pH 7.5; 8 mM MgCl2; 40 ug/ml BSA); 12-20 pmole of each primer (one of which must contain a 5-prime phosphate), 250 uM each dNTP, 2.5 U Taq DNA polymerase, 2.5 U ofTaq Extender (Stratagene).

  • The PCR cycling parameters are 1 cycle of: 4 min at 94 C, 2 min at 50 C and 2 min at 72 C; followed by 5-10 cycles of 1 min at 94 C, 2 min at 54 C and 1 min at 72 C (step 1).

  • The parental template DNA and the linear, mutagenesis-primer incorporating newly synthesized DNA are treated with DpnI (10 U) and Pfu DNA polymerase (2.5U). This results in the DpnI digestion of the in vivo methylated parental template and hybrid DNA and the removal, by Pfu DNA polymerase, of the TaqDNA polymerase-extended base(s) on the linear PCR product.

  • The reaction is incubated at 37 C for 30 min and then transferred to 72 C for an additional 30 min (step 2).

  • Mutagenesis buffer (1x, 115 ul, containing 0.5 mM ATP) is added to the DpnI-digested, Pfu DNA polymerase-polished PCR products.

  • The solution is mixed and 10 ul is removed to a new microfuge tube and T4 DNA ligase (2-4 U) added.

  • The ligation is incubated for greater than 60 min at 37 C (step 3).

  • The treated solution is transformed into competent E. coli (step 4).


相关文章

伯乐公司通过战略收购与平台推出扩展四款数字PCR产品系列

全球生命科学研究和临床诊断产品领域的领导者伯乐实验室有限公司(纽约证券交易所代码:BIO和BIO.B)近日宣布推出四款新的微滴式数字PCR(ddPCR™)平台。新推出的仪器包括伯乐公司的QXConti......

医疗器械优先审批申请审核结果公示(2025年第6号)

国家药品监督管理局医疗器械技术审评中心发布医疗器械优先审批申请审核结果公示(2025年第6号),同意了苏州淦江生物技术有限公司申请的运动神经元存活基因1(SMN1)检测试剂盒(PCR-荧光探针熔解曲线......

3280万元华中农业大学大批仪器采购意向涉PCR、蛋白纯化等

近日,华中农业大学发布多个实验室仪器设备政府采购意向,采购的产品包括:超高分辨多色快速成像系统、荧光定量PCR仪、显微镜、蛋白纯化系统、分析天平、电泳仪、摇床、细胞破碎仪、核酸转染系统、纯水系统等,采......

伯乐领投Geneoscopy公司完成1.05亿美元的C轮融资

Geneoscopy公司周三宣布已完成1.05亿美元的C轮融资。此轮融资由伯乐实验室领投,两家公司在一份联合声明中表示,这笔资金将用于支持Geneoscopy公司无创结直肠癌筛查检测的推出。参与此次融......

9.5个亿!伯乐收购PCR公司

波兰生命科学公司ScopeFluidics近日表示,在收到交易的最后一笔款项后,该公司最近敲定了以1.3亿美元(约合9.5亿元人民币)的价格将其子公司CuriosityDiagnostics出售给Bi......

北京市聚合酶链反应(PCR)检验实验室检查指南(2024版)

京药监发〔2024〕261号各区市场监管局,房山区燕山市场监管分局,市市场监管局机场分局,经开区商务金融局,市药监局各分局,各相关事业单位:为深入贯彻落实医疗器械生产监管相关法规要求,进一步规范北京市......

预算近716万某部医院PCR分析仪、显微镜等设备招标采购

项目概况2024年度攻坚第十二批医疗设备采购项目(1-5包)招标项目的潜在投标人应在通利晟信管理咨询有限公司3楼(大连市沙河口区万岁街135号)获取招标文件,并于2024年10月09日09点30分(北......

110万,上海捷谱仪器中标上海中医药大学附属曙光医院数字PCR系统

根据全国公共资源交易平台公示,上海中医药大学附属曙光医院数字PCR系统等项目中标(成交)结果公布。其中,数字PCR系统的中标供应商为上海捷谱仪器设备有限公司,中标金额为1098500.00元。该公司的......

109万,上海捷谱中标上海中医药大学附属曙光医院数字PCR系统

2024年9月3日,上海中医药大学附属曙光医院数字PCR系统等项目中标(成交)结果公布。其中,数字PCR系统的中标供应商为上海捷谱仪器设备有限公司,中标金额为1098500.00元。该公司的投标文件无......

盛景不再?2024上半年PCR中标盘点,三家成交额超千万

书接上回,PCR市场如何?本网进行了数据整理,意在为各位读者提供参考。上篇文章中提到近期PCR仪新品及上市情况(2024PCR仪市场亮点:国械注准新动态与前沿新品概览),共计20款仪器问世,各厂商都在......